TY  - JOUR
A1  - Gerlach, Manfred
A1  - Maetzler, Walter
A1  - Broich, Karl
A1  - Hampel, Harald
A1  - Rems, Lucas
A1  - Reum, Torsten
A1  - Riederer, Peter
A1  - Stöffler, Albrecht
A1  - Streffer, Johannes
A1  - Berg, Daniela
T1  - Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics
JF  - Journal of Neural Transmission
N2  - Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson’s disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies.
KW  - Parkinson’s disease
KW  - Disease-modifying therapies
KW  - Neuroprotection
KW  - Biomarkers
KW  - Surrogate endpoints
KW  - Drug development
KW  - Disease progression
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133856
VL  - 119
IS  - 1
ER  - 
TY  - JOUR
A1  - Gerlach, Manfred
A1  - Maetzler, Walter
A1  - Broich, Karl
A1  - Hampel, Harald
A1  - Rems, Lucas
A1  - Reum, Torsten
A1  - Riederer, Peter
A1  - Stäffler, Albrecht
A1  - Streffer, Johannes
A1  - Berg, Daniela
T1  - Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
JF  - Journal of Neural Transmission
N2  - Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson’s disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies.
KW  - disease progression
KW  - biomarkers
KW  - neuroprotection
KW  - disease-modifying therapies
KW  - Parkinson’s disease
KW  - surrogate endpoints
KW  - drug development
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-125375
VL  - 119
IS  - 1
ER  -